[{"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.", "fullTimeEmployees": 16, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 48, "title": "Founder, President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 904243, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 39, "title": "Senior VP & CFO", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 505158, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy E. Yeung", "title": "VP of Legal Affairs, Head of Compliance & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 61, "title": "Senior Vice President of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 466430, "exercisedValue": 0, "unexercisedValue": 55739}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "Senior VP of Regulatory Affairs, CMC & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.27, "open": 1.28, "dayLow": 1.24, "dayHigh": 1.32, "regularMarketPreviousClose": 1.27, "regularMarketOpen": 1.28, "regularMarketDayLow": 1.24, "regularMarketDayHigh": 1.32, "beta": 2.428, "forwardPE": -2.911786, "volume": 1317952, "regularMarketVolume": 1317952, "averageVolume": 2829677, "averageVolume10days": 3093330, "averageDailyVolume10Day": 3093330, "bid": 0.9504, "ask": 1.6, "bidSize": 100, "askSize": 200, "marketCap": 103728248, "fiftyTwoWeekLow": 0.73, "fiftyTwoWeekHigh": 1.84, "fiftyDayAverage": 1.1036, "twoHundredDayAverage": 1.21705, "currency": "USD", "enterpriseValue": 72449216, "floatShares": 70097636, "sharesOutstanding": 78582000, "sharesShort": 9805787, "sharesShortPriorMonth": 7973831, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1248, "heldPercentInsiders": 0.00166, "heldPercentInstitutions": 0.08059, "shortRatio": 2.04, "shortPercentOfFloat": 0.125, "impliedSharesOutstanding": 80876304, "bookValue": 0.247, "priceToBook": 5.34413, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -32280000, "trailingEps": -0.67, "forwardEps": -0.43, "lastSplitFactor": "1:50", "lastSplitDate": 1573171200, "52WeekChange": 0.5875, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLS", "underlyingSymbol": "SLS", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "firstTradeDateEpochUtc": 1205328600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d5f0c150-9f89-3f17-8497-1832af4e7670", "messageBoardId": "finmb_262231850", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.32, "targetHighPrice": 7.5, "targetLowPrice": 4.0, "targetMeanPrice": 5.83333, "targetMedianPrice": 6.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 21031000, "totalCashPerShare": 0.299, "totalDebt": 576000, "quickRatio": 1.982, "currentRatio": 2.265, "debtToEquity": 3.624, "returnOnAssets": -1.14452, "returnOnEquity": -5.35102, "freeCashflow": -21813000, "operatingCashflow": -33074000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]